74 results on '"Crooks, Bruce"'
Search Results
52. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Shuen, Andrew Y, Lanni, Stella, Panigrahi, Gagan B, Edwards, Melissa, Yu, Lisa, Campbell, Brittany B, Mandel, Ariane, Zhang, Cindy, Zhukova, Nataliya, Alharbi, Musa, Bernstein, Mark, Bowers, Daniel C, Carroll, Sara, Cole, Kristina A, Constantini, Shlomi, Crooks, Bruce, Dvir, Rina, Farah, Roula, Hijiya, Nobuko, George, Ben, Laetsch, Theodore W, Larouche, Valerie, Lindhorst, Scott, Luiten, Rebecca C, Magimairajan, Vanan, Mason, Gary, Mason, Warren, Mordechai, Oz, Mushtaq, Naureen, Nicholas, Garth, Oren, Michael, Palma, Laura, Pedroza, Luis Alberto, Ramdas, Jagadeesh, Samuel, David, Wolfe Schneider, Kami, Seeley, Andrea, Semotiuk, Kara, Shamvil, Ashraf, Sumerauer, David, Toledano, Helen, Tomboc, Patrick, Wierman, Margaret, Van Damme, An, Lee, Yi-Yen, Zapotocky, Michal, Bouffet, Eric, Durno, Carol, Aronson, Melyssa, Gallinger, Steve, Foulkes, William D, Malkin, David, Tabori, Uri, Pearson, Christopher E, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Shuen, Andrew Y, Lanni, Stella, Panigrahi, Gagan B, Edwards, Melissa, Yu, Lisa, Campbell, Brittany B, Mandel, Ariane, Zhang, Cindy, Zhukova, Nataliya, Alharbi, Musa, Bernstein, Mark, Bowers, Daniel C, Carroll, Sara, Cole, Kristina A, Constantini, Shlomi, Crooks, Bruce, Dvir, Rina, Farah, Roula, Hijiya, Nobuko, George, Ben, Laetsch, Theodore W, Larouche, Valerie, Lindhorst, Scott, Luiten, Rebecca C, Magimairajan, Vanan, Mason, Gary, Mason, Warren, Mordechai, Oz, Mushtaq, Naureen, Nicholas, Garth, Oren, Michael, Palma, Laura, Pedroza, Luis Alberto, Ramdas, Jagadeesh, Samuel, David, Wolfe Schneider, Kami, Seeley, Andrea, Semotiuk, Kara, Shamvil, Ashraf, Sumerauer, David, Toledano, Helen, Tomboc, Patrick, Wierman, Margaret, Van Damme, An, Lee, Yi-Yen, Zapotocky, Michal, Bouffet, Eric, Durno, Carol, Aronson, Melyssa, Gallinger, Steve, Foulkes, William D, Malkin, David, Tabori, Uri, and Pearson, Christopher E
- Abstract
PURPOSE: Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. As several cancer syndromes are clinically similar, accurate diagnosis is critical to cancer screening and treatment. As genetic diagnosis is confounded by 15 or more pseudogenes and variants of uncertain significance, a robust diagnostic assay is urgently needed. We sought to determine whether an assay that directly measures MMR activity could accurately diagnose CMMRD. PATIENTS AND METHODS: In vitro MMR activity was quantified using a 3'-nicked G-T mismatched DNA substrate, which requires MSH2-MSH6 and MLH1-PMS2 for repair. We quantified MMR activity from 20 Epstein-Barr virus-transformed lymphoblastoid cell lines from patients with confirmed CMMRD. We also tested 20 lymphoblastoid cell lines from patients who were suspected for CMMRD. We also characterized MMR activity from patients with neurofibromatosis type 1, Li-Fraumeni syndrome, polymerase proofreading-associated cancer syndrome, and Lynch syndrome. RESULTS: All CMMRD cell lines had low MMR activity (n = 20; mean, 4.14 ± 1.56%) relative to controls (n = 6; mean, 44.00 ± 8.65%; P < .001). Repair was restored by complementation with the missing protein, which confirmed MMR deficiency. All cases of patients with suspected CMMRD were accurately diagnosed. Individuals with Lynch syndrome (n = 28), neurofibromatosis type 1 (n = 5), Li-Fraumeni syndrome (n = 5), and polymerase proofreading-associated cancer syndrome (n = 3) had MMR activity that was comparable to controls. To accelerate testing, we measured MMR activity directly from fresh lymphocytes, which yielded results in 8 days. CONCLUSION: On the basis of the current data set, the in vitro G-T repair assay was able to diagnose CMMRD with 100% specificity and sensitivity. Rapid diagnosis before surgery in non-neoplastic tissues could speed proper therapeutic management.
- Published
- 2019
53. 101 Re-Irradiation for Children with Recurrent Supratentorial High-Grade Glioma
- Author
-
Oliveira, Carol, primary, Laperriere, Normand J., additional, Bouffet, Eric, additional, Hawkins, Cynthia, additional, Ramaswamy, Vijay, additional, Yee, Ryan, additional, Tabori, Uri, additional, Bartels, Ute, additional, Huang, Annie, additional, Millar, Barbara-Ann, additional, Crooks, Bruce, additional, Bowes, Lynette, additional, Zelcer, Shayna, additional, and Tsang, Derek S., additional
- Published
- 2019
- Full Text
- View/download PDF
54. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
- Author
-
Guerreiro Stucklin, Ana S., primary, Ryall, Scott, additional, Fukuoka, Kohei, additional, Zapotocky, Michal, additional, Lassaletta, Alvaro, additional, Li, Christopher, additional, Bridge, Taylor, additional, Kim, Byungjin, additional, Arnoldo, Anthony, additional, Kowalski, Paul E., additional, Zhong, Yvonne, additional, Johnson, Monique, additional, Li, Claire, additional, Ramani, Arun K., additional, Siddaway, Robert, additional, Nobre, Liana Figueiredo, additional, de Antonellis, Pasqualino, additional, Dunham, Christopher, additional, Cheng, Sylvia, additional, Boué, Daniel R., additional, Finlay, Jonathan L., additional, Coven, Scott L., additional, de Prada, Inmaculada, additional, Perez-Somarriba, Marta, additional, Faria, Claudia C., additional, Grotzer, Michael A., additional, Rushing, Elisabeth, additional, Sumerauer, David, additional, Zamecnik, Josef, additional, Krskova, Lenka, additional, Garcia Ariza, Miguel, additional, Cruz, Ofelia, additional, Morales La Madrid, Andres, additional, Solano, Palma, additional, Terashima, Keita, additional, Nakano, Yoshiko, additional, Ichimura, Koichi, additional, Nagane, Motoo, additional, Sakamoto, Hiroaki, additional, Gil-da-Costa, Maria Joao, additional, Silva, Roberto, additional, Johnston, Donna L., additional, Michaud, Jean, additional, Wilson, Bev, additional, van Landeghem, Frank K. H., additional, Oviedo, Angelica, additional, McNeely, P. Daniel, additional, Crooks, Bruce, additional, Fried, Iris, additional, Zhukova, Nataliya, additional, Hansford, Jordan R., additional, Nageswararao, Amulya, additional, Garzia, Livia, additional, Shago, Mary, additional, Brudno, Michael, additional, Irwin, Meredith S., additional, Bartels, Ute, additional, Ramaswamy, Vijay, additional, Bouffet, Eric, additional, Taylor, Michael D., additional, Tabori, Uri, additional, and Hawkins, Cynthia, additional
- Published
- 2019
- Full Text
- View/download PDF
55. Repeat irradiation for children with supratentorial high‐grade glioma
- Author
-
Tsang, Derek S., primary, Oliveira, Carol, additional, Bouffet, Eric, additional, Hawkins, Cynthia, additional, Ramaswamy, Vijay, additional, Yee, Ryan, additional, Tabori, Uri, additional, Bartels, Ute, additional, Huang, Annie, additional, Millar, Barbara‐Ann, additional, Crooks, Bruce, additional, Bowes, Lynette, additional, Zelcer, Shayna, additional, and Laperriere, Normand, additional
- Published
- 2019
- Full Text
- View/download PDF
56. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue
- Author
-
Shuen, Andrew Y., primary, Lanni, Stella, additional, Panigrahi, Gagan B., additional, Edwards, Melissa, additional, Yu, Lisa, additional, Campbell, Brittany B., additional, Mandel, Ariane, additional, Zhang, Cindy, additional, Zhukova, Nataliya, additional, Alharbi, Musa, additional, Bernstein, Mark, additional, Bowers, Daniel C., additional, Carroll, Sara, additional, Cole, Kristina A., additional, Constantini, Shlomi, additional, Crooks, Bruce, additional, Dvir, Rina, additional, Farah, Roula, additional, Hijiya, Nobuko, additional, George, Ben, additional, Laetsch, Theodore W., additional, Larouche, Valerie, additional, Lindhorst, Scott, additional, Luiten, Rebecca C., additional, Magimairajan, Vanan, additional, Mason, Gary, additional, Mason, Warren, additional, Mordechai, Oz, additional, Mushtaq, Naureen, additional, Nicholas, Garth, additional, Oren, Michael, additional, Palma, Laura, additional, Pedroza, Luis Alberto, additional, Ramdas, Jagadeesh, additional, Samuel, David, additional, Wolfe Schneider, Kami, additional, Seeley, Andrea, additional, Semotiuk, Kara, additional, Shamvil, Ashraf, additional, Sumerauer, David, additional, Toledano, Helen, additional, Tomboc, Patrick, additional, Wierman, Margaret, additional, Van Damme, An, additional, Lee, Yi-Yen, additional, Zapotocky, Michal, additional, Bouffet, Eric, additional, Durno, Carol, additional, Aronson, Melyssa, additional, Gallinger, Steve, additional, Foulkes, William D., additional, Malkin, David, additional, Tabori, Uri, additional, and Pearson, Christopher E., additional
- Published
- 2019
- Full Text
- View/download PDF
57. HGG-20. DNA METHYLATION ANALYSIS OF HIGH-GRADE GLIOMA IN PATIENTS WITH MISMATCH REPAIR DEFICIENCIES
- Author
-
Dodgshun, Andrew, primary, Fukuoka, Kohei, additional, Campbell, Brittany, additional, Edwards, Melissa, additional, Sexton-Oates, Alexandra, additional, Larouche, Valérie, additional, Magimairajan, Vanan, additional, Lindhorst, Scott, additional, Oren, Michal, additional, Mason, Gary, additional, Crooks, Bruce, additional, Constantini, Shlomi, additional, Massimino, Maura, additional, Chiaravalli, Stefano, additional, Ramdas, Jagadeesh, additional, Mason, Warren, additional, Shamvil, Ashraf, additional, Farah, Roula, additional, van Damme, An, additional, Opocher, Enrico, additional, Hamid, Syed Ahmer, additional, Ziegler, David, additional, Samuel, David, additional, Cole, Kristina A, additional, Tomboc, Patrick, additional, Stearns, Duncan, additional, Thomas, Gregory, additional, Lossos, Alexander, additional, Saffery, Richard, additional, Sullivan, Michael, additional, Hansford, Jordan R, additional, Jones, David, additional, and Tabori, Uri, additional
- Published
- 2018
- Full Text
- View/download PDF
58. Isolated Penile Meatal Chronic GVHD in a Boy Following Allogeneic Transplant for JMML
- Author
-
Spicer, Carol, primary, MacLellan, Dawn, additional, Fraser, Robert, additional, Fernandez, Conrad, additional, and Crooks, Bruce, additional
- Published
- 2016
- Full Text
- View/download PDF
59. Defending the Donor: When at-Risk Siblings Cannot Consent
- Author
-
Crooks, Bruce, primary, Doyle, John, additional, Fernandez, Conrad, additional, Spicer, Carol, additional, and Shea, Sarah, additional
- Published
- 2016
- Full Text
- View/download PDF
60. What do children with cancer know about their medications?
- Author
-
MacDonald, Tamara, MacDonald, Derek, Crooks, Bruce, Collicott, Cherie, MacDonald, Tamara, MacDonald, Derek, Crooks, Bruce, and Collicott, Cherie
- Abstract
Objectives: To explore the health literacy of children diagnosed with Acute Lymphoblastic Leukemia (ALL) through their knowledge of their medications. Methods: Within the Basic Interpretive approach to qualitative research, semi-structured interviews were conducted with children from ages 6 to18 years (n=16) between May and September 2009 to determine their knowledge of medication properties, medication habits and medication teaching. REB approval was obtained. Results: The younger children (mean age 7.5 years) correctly answered, on average, 51% of the questions on colour, 26% of the questions on name, 25% of the questions on frequency, and 8% of the questions on the purposes of their medications. The older children (mean age 16 years) scored at least 35% higher for each characteristic. All of the younger children reported that physicians consistently directed medication education to parents only, and that the younger children were rarely present during these sessions. 13 of the 16 children stated that they want to learn more about and be more involved in education sessions addressing their medications. Conclusion: Children with ALL at the IWK Health Centre do not have a good knowledge of their medications, however most children expressed that they want to know more about their medications., Objetivos: Explorar la alfabetización en salud de los niños diagnosticados de leucemia linfoblástica aguda (LLA) a través de su conocimiento sobre la medicación. Métodos: Con un abordaje de Interpretación Básico de investigación cualitativa, se realizaron entrevistas semi-estructuradas a niños de 6 a 18 años (n=16) entre mayo y septiembre de 2009 para determinar su conocimiento de las propiedades de la medicación, costumbres de medicación y enseñanzas de la medicación. Se obtuvo aprobación de la Comisión de Ética. Resultados: Los niños más jóvenes (edad media 7,5 años) respondían correctamente a una media de 51% de las preguntas sobre color, 26% de las preguntas sobre el nombre, 25% de las preguntas sobre frecuencia, y 8% de las preguntas sobre objetivos de la medicación. Los niños mayores (edad media 16 años) puntuaron al menos en el 35% para cada característica. Todos los niños más jóvenes informaron que normalmente el medico realizada la educación sobre la medicación a sus padres solamente, y que los más jóvenes raramente estaban en esas sesiones. 13 de los 16 niños afirmaron que querían aprender más sobre la medicación y estar más involucrados en las sesiones educativas realizadas sobre su medicación. Conclusión: Los niños con LLA en el IWK Health Centre no tienen un buen conocimiento de sus medicaciones, sin embargo, la mayoría de los niños expresó que deseaban saber más sobre sus medicaciones.
- Published
- 2011
61. Choroid plexus tumors in children less than 36 months: the Canadian Pediatric Brain Tumor Consortium (CPBTC) experience
- Author
-
Lafay-Cousin, Lucie, primary, Keene, Daniel, additional, Carret, Anne-Sophie, additional, Fryer, Chris, additional, Brossard, Josee, additional, Crooks, Bruce, additional, Eisenstat, David, additional, Johnston, Donna, additional, Larouche, Valerie, additional, Silva, Marianna, additional, Wilson, Beverly, additional, Zelcer, Shayna, additional, Bartels, Ute, additional, and Bouffet, Eric, additional
- Published
- 2010
- Full Text
- View/download PDF
62. Langerhans cell histiocytosis: A complex recurrent disease
- Author
-
Crooks, Bruce, primary and Grenier, Danielle, additional
- Published
- 2010
- Full Text
- View/download PDF
63. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report
- Author
-
Johnston, Donna L., primary, Keene, Daniel L., additional, Lafay-Cousin, Lucie, additional, Steinbok, Paul, additional, Sung, Lillian, additional, Carret, Anne-Sophie, additional, Crooks, Bruce, additional, Strother, Douglas, additional, Wilson, Beverly, additional, Odame, Isaac, additional, Eisenstat, David D., additional, Mpofu, Chris, additional, Zelcer, Shayna, additional, Huang, Annie, additional, and Bouffet, Eric, additional
- Published
- 2007
- Full Text
- View/download PDF
64. Routine Surveillance for Bloodstream Infections in a Pediatric Hematopoietic Stem Cell Transplant Cohort: Do Patients Benefit?
- Author
-
Rigby, Heather, primary, Fernandez, Conrad V, additional, Langley, Joanne, additional, Mailman, Tim, additional, Crooks, Bruce, additional, and Higgins, Ann, additional
- Published
- 2007
- Full Text
- View/download PDF
65. Routine Surveillance for Bloodstream Infections in a Pediatric Hematopoietic Stem Cell Transplant (HSCT) Cohort: Do Patients Benefit?.
- Author
-
Fernandez, Conrad, primary, Rigby, Heather, additional, Langley, Joanne, additional, Mailman, Timothy, additional, Crooks, Bruce, additional, and Higgins, Ann, additional
- Published
- 2006
- Full Text
- View/download PDF
66. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma
- Author
-
Tabori, Uri, primary, Sung, Lillian, additional, Hukin, Juliette, additional, Laperriere, Normand, additional, Crooks, Bruce, additional, Carret, Anne-Sophie, additional, Silva, Mariana, additional, Odame, Isaac, additional, Mpofu, Chris, additional, Strother, Douglas, additional, Wilson, Beverly, additional, Samson, Yvan, additional, and Bouffet, Eric, additional
- Published
- 2006
- Full Text
- View/download PDF
67. Adenovirus Type F Subtype 41 Causing Disseminated Disease following Bone Marrow Transplantation for Immunodeficiency
- Author
-
Slatter, Mary A., primary, Read, Steven, additional, Taylor, Clive E., additional, Crooks, Bruce N. A., additional, Abinun, Mario, additional, Flood, Terence J., additional, Cant, Andrew J., additional, Wright, Christopher, additional, and Gennery, Andrew R., additional
- Published
- 2005
- Full Text
- View/download PDF
68. Mixed Donor Chimerism and Low level alpha-L-iduronidase Expression May Be Adequate for Neurodevelopmental Protection in Hurler’s Syndrome.
- Author
-
Conway, Jennifer, primary, Dyack, Sarah, additional, Crooks, Bruce N.A., additional, Schmidt, Matthias, additional, and Fernandez, Conrad V., additional
- Published
- 2004
- Full Text
- View/download PDF
69. Predictive dialing plus professional staff - the secret to service agency's growth
- Author
-
Crooks, Bruce
- Subjects
Telecommunications Marketing Corp. -- Equipment and supplies ,Marketing industry -- Management ,Telemarketing -- Equipment and supplies ,Advertising, marketing and public relations ,Business - Abstract
As manager of telecommunications for Telecommunications Marketing Corporation (TMC), I have seen our company grow at an average rate of 33 percent per year for the last four years. This [...]
- Published
- 1991
70. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
- Author
-
Ljungman, Per, Deliliers, Giorgio Lambertenghi, Platzbecker, Uwe, Matthes-Martin, Susanne, Bacigalupo, Andrea, Einsele, Hermann, Ullmann, Johanna, Musso, Maurizio, Trenschel, Rudolf, Ribaud, Patricia, Bornhäuser, Martin, Cesaro, Simone, Crooks, Bruce, Dekker, Adrian, Gratecos, Nicole, Klingebiel, Thomas, Tagliaferri, Elena, Ullmann, Andrew J., Wacker, Pierre, and Cordonnier, Catherine
- Abstract
A retrospective study was performed to collect information regarding efficacy and toxicity of cidofovir (CDV) in allogeneic stem cell transplant patients. Data were available on 82 patients. The indications for therapy were cytomegalovirus (CMV) disease in 20 patients, primary preemptive therapy in 24 patients, and secondary preemptive therapy in 38 patients. Of the patients, 47 had received previous antiviral therapy with ganciclovir, foscarnet, or both drugs. The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients. The duration of therapy ranged from 1 to 134 days (median, 22 days). All patients received probenecid and prehydration. Ten of 20 (50%) patients who were treated for CMV disease (9 of 16 with pneumonia) responded to CDV therapy, as did 25 of 38 (66%) patients who had failed or relapsed after previous preemptive therapy and 15 of 24 (62%) patients in whom CDV was used as the primary preemptive therapy. Of the patients, 21 (25.6%) developed renal toxicity that remained after cessation of therapy in 12 patients. Fifteen patients developed other toxicities that were potentially due to CDV or the concomitantly given probenecid. No toxicity was seen in 45 (61.6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy.
- Published
- 2001
- Full Text
- View/download PDF
71. A Case Series of TERC Varianttelomere Biology Disorders in Unrelated Families from Eastern Canada
- Author
-
Harrigan, Amye M., MacDonald, Shelley, Crooks, Bruce N., Dyack, Sarah, and Trottier, Amy M.
- Abstract
TERCvariant telomere biology disorders are a rare and heterogenous group of disorders that arise from germline variants in TERC, a gene that encodes for the RNA component of telomerase. Variants in TERClead to accelerated telomere attrition and can manifest as a wide array of clinical phenotypes affecting multiple organ systems. In this case series, we aim to add to the literature describing TERCvariant telomere biology disorders by reporting cases from two unrelated families from Eastern Canada, one of whom was found to have a novel germline TERCvariant and the other had a unique phenotypic presentation of previously described TERCvariant.
- Published
- 2020
- Full Text
- View/download PDF
72. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
- Author
-
Erker C, Mynarek M, Bailey S, Mazewski CM, Baroni L, Massimino M, Hukin J, Aguilera D, Cappellano AM, Ramaswamy V, Lassaletta A, Perreault S, Kline CN, Rajagopal R, Michaiel G, Zapotocky M, Santa-Maria Lopez V, La Madrid AM, Cacciotti C, Sandler ES, Hoffman LM, Klawinski D, Khan S, Salloum R, Hoppmann AL, Larouche V, Dorris K, Toledano H, Gilheeney SW, Abdelbaki MS, Wilson B, Tsang DS, Knipstein J, Oren MY, Shah S, Murray JC, Ginn KF, Wang ZJ, Fleischhack G, Obrecht D, Tonn S, Harrod VL, Matheson K, Crooks B, Strother DR, Cohen KJ, Hansford JR, Mueller S, Margol A, Gajjar A, Dhall G, Finlay JL, Northcott PA, Rutkowski S, Clifford SC, Robinson G, Bouffet E, and Lafay-Cousin L
- Subjects
- Child, Humans, Infant, Child, Preschool, Cohort Studies, Prospective Studies, Hedgehog Proteins, Neoplasm Recurrence, Local, Chronic Disease, Medulloblastoma radiotherapy, Craniospinal Irradiation adverse effects, Brain Neoplasms therapy, Cerebellar Neoplasms radiotherapy
- Abstract
Purpose: Infant and young childhood medulloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive late effects. Unfortunately, many children relapse. The purpose of this study was to assess salvage strategies and prognostic features of patients with iMB who relapse after CSI-sparing therapy., Methods: We assembled a large international cohort of 380 patients with relapsed iMB, age younger than 6 years, and initially treated without CSI. Univariable and multivariable Cox models of postrelapse survival (PRS) were conducted for those treated with curative intent using propensity score analyses to account for confounding factors., Results: The 3-year PRS, for 294 patients treated with curative intent, was 52.4% (95% CI, 46.4 to 58.3) with a median time to relapse from diagnosis of 11 months. Molecular subgrouping was available for 150 patients treated with curative intent, and 3-year PRS for sonic hedgehog (SHH), group 4, and group 3 were 60%, 84%, and 18% ( P = .0187), respectively. In multivariable analysis, localized relapse ( P = .0073), SHH molecular subgroup ( P = .0103), CSI use after relapse ( P = .0161), and age ≥ 36 months at initial diagnosis ( P = .0494) were associated with improved survival. Most patients (73%) received salvage CSI, and although salvage chemotherapy was not significant in multivariable analysis, its use might be beneficial for a subset of children receiving salvage CSI < 35 Gy ( P = .007)., Conclusion: A substantial proportion of patients with relapsed iMB are salvaged after initial CSI-sparing approaches. Patients with SHH subgroup, localized relapse, older age at initial diagnosis, and those receiving salvage CSI show improved PRS. Future prospective studies should investigate optimal CSI doses and the role of salvage chemotherapy in this population., Competing Interests: Craig ErkerConsulting or Advisory Role: Novartis Canada Pharmaceuticals Inc Martin MynarekEmployment: Novartis, BioNTech SE Maura MassiminoConsulting or Advisory Role: Oncoscience, Novartis Juliette HukinStock and Other Ownership Interests: AbbVieConsulting or Advisory Role: AstraZeneca, Novartis Vijay RamaswamyHonoraria: AstraZenecaConsulting or Advisory Role: AstraZeneca Canada Alvaro LassalettaStock and Other Ownership Interests: Gilead SciencesConsulting or Advisory Role: Jazz Pharmaceuticals, Servier, Alexion Pharmaceuticals Sébastien PerreaultLeadership: BayerStock and Other Ownership Interests: NovocureHonoraria: BayerConsulting or Advisory Role: BayerSpeakers' Bureau: BayerExpert Testimony: Bayer Cassie N. KlineResearch Funding: Regeneron (Inst), Curis (Inst), Midatech Pharma (Inst), Ipsen (Inst), Day One Therapeutics (Inst), Bristol Myers Squibb (Inst), Kazia Therapeutics (Inst), Chimerix (Inst) Eric S. SandlerConsulting or Advisory Role: Protara Therapeutics Lindsey M. HoffmanHonoraria: AstraZeneca Kathleen DorrisStock and Other Ownership Interests: Amgen, Gilead SciencesConsulting or Advisory Role: Day One Biopharmaceuticals Helen ToledanoConsulting or Advisory Role: AstraZeneca, Novartis Derek S. TsangTravel, Accommodations, Expenses: Mevion Medical Systems Jeffrey KnipsteinEmployment: PRA Health Sciences, ServierConsulting or Advisory Role: Atheneum Zhihong J. WangHonoraria: AstraZenecaConsulting or Advisory Role: AstraZenecaSpeakers' Bureau: AstraZeneca Kenneth J. CohenConsulting or Advisory Role: Novartis, Bristol Myers Squibb, DNAtrixResearch Funding: Novartis, Bristol Myers Squibb Jordan R. HansfordStock and Other Ownership Interests: AnteotechConsulting or Advisory Role: Bayer Sabine MuellerResearch Funding: Regeneron (Inst), DayOne Pharmaceuticals (Inst), Curis Pharamceuticals (Inst), Curis Pharamceuticals (Inst), Bristol Myers Squibb (Inst) Amar GajjarConsulting or Advisory Role: Roche/Genentech, QED Therapeutics, Day One Therapeutics, Geanno BioResearch Funding: Genentech (Inst), Kazia Therapeutics (Inst) Stefan RutkowskiConsulting or Advisory Role: Bristol Myers Squibb GmbH & Co. KGaA, Germany, Celgene, Roche Pharma AG, Grenzach-Wyhlen, Bayer Germany Giles RobinsonResearch Funding: Novartis (Inst), Genentech/Roche (Inst), Novartis (Inst), SpringWorks Therapeutics (Inst) Eric BouffetConsulting or Advisory Role: NovartisResearch Funding: Roche (Inst) Lucie Lafay-CousinHonoraria: Servier, Innomar StrategiesNo other potential conflicts of interest were reported.
- Published
- 2023
- Full Text
- View/download PDF
73. Removing barriers to accessing medical cannabis for paediatric patients.
- Author
-
Huntsman RJ, Elliott J, Lewis E, Moore-Hepburn C, Alcorn J, Mansell H, Appendino JP, Bélanger RE, Corley S, Crooks B, Denny AM, Finkelstein Y, Finley A, Fung R, Gilpin A, Litalien C, Jacobs J, Oberlander TF, Palm A, Palm J, Polewicz M, Quinn D, Rassekh SR, Repetski A, Rieder MJ, Robson-McKay A, Seifert B, Shackelford A, Siden H, Szafron M, 't Jong G, Vaillancourt R, and Kelly LE
- Abstract
Medical cannabis (MC) may offer therapeutic benefits for children with complex neurological conditions and chronic diseases. In Canada, parents, and caregivers frequently report encountering barriers when accessing MC for their children. These include negative preconceived notions about risks and benefits, challenges connecting with a knowledgeable healthcare provider (HCP), the high cost of MC products, and navigating MC product shortages. In this manuscript, we explore several of these barriers and provide recommendations to decision-makers to enable a family-centered and evidence-based approach to MC medicine and research for children., Competing Interests: RJH and LEK served on Health Canada’s Scientific Advisory Committee on Health Products Containing Cannabis whose views are not reflected in this manuscript. RJH received a grant from the Jim Pattison Children’s Hospital Foundation for a study on medical cannabis in childhood refractory epilepsy and was Co-Chair, Health Canada Scientific Advisory Committee on Health Products Containing Cannabis (an unpaid position). EL received speaking fees from Spectrum Therapeutics and holds leadership positions in the following groups: Jamaican Medical Cannabis Corporation (unpaid position), Medical Cannabis Clinicians Society (UK), Canadian Collaborative for Childhood Cannabinoid Therapeutics, MedCan Support and Canadian Patient Advocacy & Support Services. CM-H is the controlling shareholder of a small publicly traded company that made an incremental $1.7M investment in a biotechnology company involved in medical research related to minor cannabinoids. JA has participated in an advisory board for Zyus Life Science. REB is a member of the Advisory Council, Drug-Free Kids Canada, and was Co-Chair of the Cannabis Project Advisory Group, Canadian Paediatric Society (both unpaid positions). SC holds a leadership position on the Network of Networks (N2) Board of Directors. AG reports that this article was researched and written prior to her employment at Health Canada and any views, opinions, and recommendations expressed within are those of the authors and do not reflect the position of Health Canada and/or the Government of Canada. JJ received grants from NSERC, CIHR, AMA Pediatrics, and Alberta Children’s Hospital Foundation, consulting fees from EISAI, UCB, and PENDOPHARM, payment/honoraria from EISAI, UCB, PENDOPHARM, and SUNOVION, and travel reimbursement from Neurocrine. JJ also holds leadership positions in the American Epilepsy Society, the Canadian League Against Epilepsy, and Hope for Hypothalamic Hamartomas. MJR is a member of the Paediatrics & Child Health editorial board. Another editor was responsible for overseeing the peer review of this manuscript. AS is the founder of Shackelford Pharma., an emerging medical cannabis company. There is also a provisional patent application filed, but not yet issued, on behalf of Shackelford Pharma, Inc. RV was director of the Department of Pediatric Pharmacy, Children’s Hospital of Eastern Ontario when this manuscript was written and submitted for publication but is now Vice President of Pharmacy Affairs for BCE Pharma. He has received consulting fees from Harvest Medicine Clinic and recently concluded an 8-year term as a Director of the International Pharmaceutical Federation Foundation. LEK holds a Board of Directors position at the Canadian Consortium for the Investigation of Cannabinoids and holds funding from the Canadian Institutes of Health Research, the Canadian Cancer Society, and the SickKids Foundation for C4T. She holds a Mitacs Accelerate grant for a separate project in partnership with Canopy Growth. There are no other disclosures., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Paediatric Society.)
- Published
- 2023
- Full Text
- View/download PDF
74. What do children with cancer know about their medications?
- Author
-
Macdonald T, Macdonald D, Crooks B, and Collicott C
- Abstract
Objective: To explore the health literacy of children diagnosed with Acute Lymphoblastic Leukemia (ALL) through their knowledge of their medications., Methods: Within the Basic Interpretive approach to qualitative research, semi-structured interviews were conducted with children from ages 6 to18 years (n=16) between May and September 2009 to determine their knowledge of medication properties, medication habits and medication teaching. REB approval was obtained., Results: The younger children (mean age 7.5 years) correctly answered, on average, 51% of the questions on colour, 26% of the questions on name, 25% of the questions on frequency, and 8% of the questions on the purposes of their medications. The older children (mean age 16 years) scored at least 35% higher for each characteristic. All of the younger children reported that physicians consistently directed medication education to parents only, and that the younger children were rarely present during these sessions. 13 of the 16 children stated that they want to learn more about and be more involved in education sessions addressing their medications., Conclusions: Children with ALL at the IWK Health Centre do not have a good knowledge of their medications, however most children expressed that they want to know more about their medications.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.